Journals / Troia Tıp Dergisi / 2026 / Cilt: 7 Sayı: 2

Diagnostic performance of preoperative 18F-FDG PET/CT in detecting axillary lymph node metastasis in breast cancer

Meme kanserinde preoperatif 18F-FDG PET/BT’nin aksiller lenf nodu metastazını saptamadaki tanısal performansı

Özgür Yıldırım(Çanakkale Mehmet Akif ersoy devlet hastanesi)0009-0009-3736-7117
Hasan Deniz Demir(mehmet akif ersoy devlet hastanesi)0000-0001-5152-6473
Mehmet Ali Karacaer(mehmet akif ersoy devlet hastanesi)0000-0001-9357-0851
Pages
89–98
Publication Date
2026-05-31
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, PET/CT should be regarded as a complementary rather than definitive tool for axillary staging in selected breast cancer patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the diagnostic performance of axillary lymph node SUVmax measured on preoperative 18F-FDG PET/CT in predicting pathological axillary metastasis and to investigate clinicopathological and imaging factors associated with axillary involvement in breast cancer.
📊
Key Findings & Data:Methods: This single-center retrospective study included 62 selected patients who underwent clinically indicated preoperative PET/CT between 2021 and 2025 and had postoperative axillary pathological evaluation.
💡
Conclusion & Impact:Therefore, PET/CT should be regarded as a complementary rather than definitive tool for axillary staging in selected breast cancer patients.
🔬Design:Modeling & Simulation
📍Scope:2021 Verileri
⚙️Variables:Meme Neoplazmları · Pozitron Emisyon Tomografisi ve Bilgisayarlı Tomografi · Florodeoksiglukoz F18

Abstract

Objective: To evaluate the diagnostic performance of axillary lymph node SUVmax measured on preoperative 18F-FDG PET/CT in predicting pathological axillary metastasis and to investigate clinicopathological and imaging factors associated with axillary involvement in breast cancer. Methods: This single-center retrospective study included 62 selected patients who underwent clinically indicated preoperative PET/CT between 2021 and 2025 and had postoperative axillary pathological evaluation. Histopathology was accepted as the reference standard. Demographic, clinical, and imaging variables were analyzed. The optimal SUVmax cut-off was determined using ROC analysis, and variables associated with axillary metastasis were explored using multivariable logistic regression. Results: Pathological axillary metastasis was detected in 34 patients (54.8%). Advanced T stage was significantly associated with metastasis (p=0.009). Axillary lymph node short-axis diameter and SUVmax were significantly higher in the metastasis-positive group (p<0.001 and p=0.001, respectively). The AUC for SUVmax was 0.742, with a sensitivity of 55.9% and specificity of 78.6% at a cut-off value of 1.5. In multivariable analysis, only axillary lymph node short-axis diameter remained statistically significant (p=0.006), whereas SUVmax did not. Conclusion: Preoperative axillary lymph node SUVmax on 18F-FDG PET/CT showed moderate discriminatory ability for pathological axillary metastasis, but did not remain an independent predictor in the dichotomized multivariable model after adjustment for clinicopathological and morphologic imaging features. Axillary lymph node short-axis diameter remained the only independent imaging correlate. Therefore, PET/CT should be regarded as a complementary rather than definitive tool for axillary staging in selected breast cancer patients.

Özet

Amaç: Bu çalışmada, meme kanserli hastalarda preoperatif 18F-FDG PET/BT’de ölçülen aksiller lenf nodu SUVmax değerinin patolojik aksiller metastazı öngörmedeki tanısal performansının değerlendirilmesi ve aksiller tutulum ile ilişkili klinikopatolojik ve görüntüleme faktörlerinin araştırılması amaçlandı. Yöntem: Tek merkezli retrospektif çalışmaya, 2021–2025 yılları arasında klinik endikasyonla preoperatif PET/BT çekilen ve cerrahi sonrası aksiller patolojik değerlendirmesi bulunan seçilmiş 62 hasta dahil edildi. Histopatolojik inceleme referans standart olarak kabul edildi. Demografik, klinik ve görüntüleme değişkenleri analiz edildi. SUVmax için optimal kesim değeri ROC analizi ile belirlendi ve aksiller metastaz ile ilişkili değişkenler çok değişkenli lojistik regresyon analizi ile araştırıldı. Bulgular: Hastaların 34’ünde (%54,8) patolojik aksiller metastaz saptandı. İleri T evresi metastaz ile anlamlı ilişkili bulundu (p=0,009). Aksiller lenf nodu kısa aks çapı ve SUVmax değeri metastaz pozitif grupta anlamlı olarak daha yüksekti (sırasıyla p<0,001 ve p=0,001). ROC analizinde SUVmax için eğri altında kalan alan 0,742 olup, 1,5 kesim değerinde duyarlılık %55,9 ve özgüllük %78,6 olarak hesaplandı. Çok değişkenli analizde yalnızca aksiller lenf nodu kısa aks çapı anlamlı kalırken (p=0,006), SUVmax anlamlılığını korumadı. Sonuç: Preoperatif 18F-FDG PET/BT’de ölçülen aksiller lenf nodu SUVmax değeri, patolojik aksiller metastazı öngörmede orta düzeyde ayırt edici performans göstermiş, ancak klinikopatolojik ve morfolojik görüntüleme özellikleri için düzeltme yapıldığında dikotomize çok değişkenli modelde bağımsız bir belirleyici olarak kalmamıştır. Aksiller lenf nodu kısa aks çapı ise bağımsız kalan tek görüntüleme belirteci olmuştur. Bu nedenle PET/BT, seçilmiş meme kanseri hastalarında aksiller evrelemede kesin bir yöntemden çok tamamlayıcı bir araç olarak değerlendirilmelidir.

🔖

Cite This Article

Yıldırım, Ö., Demir, H. D., Karacaer, M. A. (2026). Diagnostic performance of preoperative 18F-FDG PET/CT in detecting axillary lymph node metastasis in breast cancer. Troia Tıp Dergisi, Cilt: 7 Sayı: 2, 89–98. https://doi.org/10.55665/troiamedj.1935221

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
  2. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26.
  3. Lyman GH, Somerfield MR, Bosserman LD, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(5):561-4.
  4. Groheux D, Cochet A, Humbert O, et al. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(Suppl 1):17S-26S.
  5. Ulaner GA. PET/CT for patients with breast cancer: where is the clinical impact? AJR Am J Roentgenol. 2019;213:254-65.
  6. Zhang J, Shi X, Xiao Y, et al. Early SUVmax is the best predictor of axillary lymph node metastasis in stage III breast cancers. Quant Imaging Med Surg. 2021;11:1680-91.
  7. Zhang X, Liu Y, Luo H, et al. PET/CT and MRI for identifying axillary lymph node metastases in breast cancer patients: systematic review and meta-analysis. J Magn Reson Imaging. 2020;52:1840-51.
  8. Kitajima K, Fukushima K, Miyoshi Y, et al. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. Jpn J Radiol. 2016;34:220-8.
  9. Yilmaz L, Kus T, Sanli DET. Development of a preoperative nomogram to identify low-risk early-stage breast cancer patients eligible for SLNB omission. World J Surg Oncol. 2025;23:268.
  10. Vaz SC, Woll JPP, Cardoso F, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706-32.
  11. Park KU, Somerfield MR, Anne N, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43:1720-41.
  12. Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159-82.